BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 03/06/2026

Vanda Pharmaceuticals to Face FDA Hearing on Proposed Refusal of HETLIOZ Supplemental Approval

The FDA is holding a public hearing on Vanda Pharmaceuticals' proposal to refuse approval of a supplemental new drug application for HETLIOZ (tasimelteon) to treat jet lag disorder, following a timely request from the company.

Source: Federal Register — Health and Human ServicesOpen original release →